---
schema_version: "secwatch.filing_event.v1"
accession: "0000200406-26-000146"
form_type: "8-K"
ticker: "JNJ"
cik: "0000200406"
company_name: "JOHNSON & JOHNSON"
filed_at: "2026-07-15T11:49:04+00:00"
generated_at: "2026-07-15T11:50:12.856597+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# JNJ Q2 2026 revenue up 6.6% to $25.3B; adjusted EPS $2.90 (+4.7%)

## Summary
- Q2 sales $25,310M (+6.6% operational, +1.0% currency); GAAP net earnings $5,534M (-0.1%).
- GAAP diluted EPS $2.27 (-0.9%); adjusted diluted EPS $2.90 (+4.7%).
- Innovative Medicine sales $16,384M (+7.8%); MedTech $8,926M (+4.5%).
- US sales $14,533M (+7.3%); International $10,777M (+5.7%).

## SEC filing metadata
- accession: 0000200406-26-000146
- form_type: 8-K
- ticker: JNJ
- cik: 0000200406
- company_name: JOHNSON & JOHNSON
- filed_at: 2026-07-15T11:49:04+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/200406/000020040626000146/0000200406-26-000146-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/200406/000020040626000146/jnj-20260715.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000200406-26-000146
- JSON: https://secwatch.observer/filing/0000200406-26-000146.json
- Plain text: https://secwatch.observer/filing/0000200406-26-000146.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.